National and Kapodistrian University of Athens
Μελέτη της προθυμίας πληρωμής ηλικιωμένων διαβητικών για την αντιμετώπιση των ειδικών επιπλοκών του σακχαρώδη διαβήτη
Abstract
dc:descriptionIntroduction: Diabetic retinopathy (DR), neuropathy (DNU) and nephropathy (DNP) are frequent diabetes mellitus (DM) complications, and incidence increases with diabetes duration: patients with DM for 20 years have 90% probability for DR or DNU and 40% for DNP. Aim: This study was conducted to measure how diabetic patients value risk reduction of DM complications, and estimate the maximum amount of money and percentage of monthly income these patients would pay for reduction of DR, DNU and DNP risk. Methods: All patients gave written consent. 419 DM patients, aged ≥60 years were evaluated using «willingness to pay» (WTP) for cost-benefit analysis. After receiving background information, patients were asked how much money they would pay per month for a drug that would reduce their DR and DNU risk by 30%, 60% or 90%, and DNP risk by 20% or 40%. Patients also indicated the importance of risk reduction on a 10-degree scale (0 = not important, 10 = extremely important). Data collected included demographic information, diabetes duration, presence of DR, DNU, DNP or other symptoms, and whether patients knew someone with DR, DNU or DNP. Data normality was assessed with the Kolmogorov-Smirnov test. Differences between more groups (by education level, diabetes duration or monthly income) were evaluated with the Kruskal-Wallis test. The Mann-Whitney test was used to compare groups (men vs. women, knowing vs. not knowing someone with DM, having vs. not having DR, DNU or DNP) and for post-hoc comparisons. Factors influencing “WTP” were identified with logistic regression, using “WTP” > a certain income percentage as binary dependent variable. P values <0.05 were considered significant. Results: Patients having DR or DNU were willing to pay more for risk reduction (DR: p=0.002, p=0.007 and p=0.000 for reduction by 30, 60 or 90% respectively; DNU: p=0.002, p=0.002 and p=0.001 for reduction by 30, 60 and 90%, respectively). Patients having DM for >10 years were willing to pay more (DR: p=0.026, p=0.002 and p=0.000 for risk reduction by 30, 60 or 90% respectively; DNP: p=0.000, p=0.000 for risk reduction by 20 and 40% respectively, DNU: p=0.031, p=0.028 and p=0.003 for risk reduction by 30, 60 or 90% respectively). Diabetics using insulin were willing to pay more for risk reduction to 0% (p=0.002 for DR and DNP, p=0.003 for DNU). Diabetics knowing other diabetics were also willing to pay more (DR: p=0.032, p=0.017 and p=0.001 for reduction by 30, 60 or 90% respectively; DNP: p=0.047 and p=0.004 for reduction by 20% and 40%, respectively; DNU: p=0.025 for 30% and 90% reduction and p=0.019 for 60% reduction). Higher education and income were associated with willingness to pay more for risk reduction. Conclusions: DM complication risk reduction is important to DM patients, especially those having DM for >10 years, experiencing DM complications, or knowing someone with DM. Education and monthly income significantly influence the perceived value of DM complication risk reduction.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2011
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Vlahou, Chrisi
- Βλάχου, Χρυσή
Subjects
dc:subject × 20- Προθυμία πληρωμής
- Διαβητική αμφιβληστροειδοπάθεια
- Διαβητική νεφροπάθεια
- Διαβητική νευροπάθεια
- Ανάλυση κόστους - ωφέλειας
- Σακχαρώδης διαβήτης
- Ηλικιωμένοι διαβητικοί
- Ενδεχόμενη αποτίμηση
- Willingness to pay
- Diabetic retinopathy
- Diabetic nephropathy
- Diabetic neuropathy
- Cost benefit analysis
- Diabetes mellitus
- Old diabetics
- Contingent valuation
- Ιατρική και Επιστήμες Υγείας
- Επιστήμες Υγείας
- Medical and Health Sciences
- Health Sciences
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/26086